Propanc Biopharma, Inc. 8-K

What Happened

• Propanc Biopharma, Inc. filed an 8‑K reporting that Dr. Julian Kenyon retired from the Company’s Board of Directors effective February 20, 2026, to focus on his personal and family life. Dr. Kenyon will remain involved as a medical advisor to the Company.
• The Board filled the resulting vacancy that same day by appointing Dr. Ralf Brandt to serve as a director until his removal or resignation. A Director Agreement between the Company and Dr. Brandt dated February 20, 2026 was filed as Exhibit 10.1.

Key Details

• Date of change: February 20, 2026.
• Outgoing director: Dr. Julian Kenyon — will continue as medical advisor.
• Incoming director: Dr. Ralf Brandt — >30 years in pharma and oncology research; has advanced 50+ compounds to clinical studies, holds 5 international patents, authored 27 peer‑reviewed publications; former leadership roles include CEO/Founder of vivoPharm entities, President Discovery at CGIX and VYANT Bio Inc., and positions at Novartis and Bionomics Ltd.
• Filing: Form 8‑K (Items 5.02 and 9.01), Exhibit 10.1 (Director Agreement).

Why It Matters

• Board composition change is material governance news for investors: it signals continuity in scientific oversight (Dr. Kenyon remains as a medical advisor) while adding a director with deep drug‑development and translational research experience, which may strengthen the company’s R&D and regulatory capabilities.
• The filing does not disclose compensation, equity grants, or direct financial impact from the change. Investors should monitor future disclosures for any related arrangements or strategic shifts.